Peanut Placebo, Nocebo, PCSK9: Lipid lowering and peanut allergy

Subscribe on iTunes

This week: New studies of PCSK9 inhibitors for lipid lowering and a randomized controlled trial of early peanut exposure to prevent allergy

Fahad and Amol want you to understand the following:

1. PCSK9 inhibitors are new cholesterol-lowering monoclonal antibodies that have been shown to reduce LDL beyond standard therapy with statins and have been associated with reduced cardiovascular events in patients at high cardiovascular risk.

2. The LEAP study showed that early and sustained exposure to peanuts in infants at high risk of peanut allergy resulted in a reduced incidence of peanut allergy at 5 years.

Continuing Medical Education

Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.

The papers

MS Sabatine et al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 Mar 15. [EPub]. (PubMed).

JG Robinson et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 Mar 15. [EPub]. (PubMed).

G Du Toit et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med. 2015 Feb 26;372(9):803-13. (PubMed).

Good stuff

New Dosages of Old Drugs Are Used to Raise Their Prices. Barry Meier. New York Times. 2015 Feb 10.

DB Kramer, AS Kesselheim. The Watchman Saga – Closure at Last? N Engl J Med. 2015 Mar;372:994-995.

Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more